Volume 11, Issue 1 (2025)                   IEM 2025, 11(1): 43-50 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Seyyed Rezaei S A, Moghimi A, Asgharzadeh V, Mahdavi Poor B, Asgharzadeh M, Jalaei Nobari H, et al . Infections and Their Impact on Multiple Sclerosis. IEM 2025; 11 (1) :43-50
URL: http://iem.modares.ac.ir/article-4-77346-en.html
1- Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
4- Infectious and Tropical Diseases Research Center, and Faculty of Paramedicine, Tabriz University of Medical Sciences, Tabriz, Iran
5- Biotechnology Research Center, and Faculty of Paramedicine, Tabriz University of Medical Sciences, Tabriz, Iran
6- Department of Islamic Studies, Faculty of Paramedicine, Tabriz University of Medical Sciences, Tabriz, Iran
7- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
8- Department of Cardiovascular Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
9- Faculty of Paramedicine, Tabriz University of Medical Sciences, Tabriz, Iran , j.rashedi@tbzmed.ac.ir
Abstract:   (452 Views)
Aims: Multiple sclerosis (MS) is a prevalent central nervous system (CNS) disorder characterized by inflammation and demyelination of nerves. The incidence of this disease has markedly risen in diverse regions, including the Middle East. Any factor that alters the quality and quantity of immune system components or influences the migration of immune cells toward the CNS may contribute to MS development. Evidence suggests that paragenetic, genetic, and environmental factors may be involved in increasing MS risk. This study aimed to investigate the effect of various infections on MS incidence.
 
Materials & Methods: This study included 475 MS patients and 260 healthy individuals from the Azeri population of East Azerbaijan province. Both groups filled out a questionnaire about their history of exposure to specific pathogens and infections before the age of 15.The relationship between a history of various infections and MS risk was examined.Findings: Mycoplasma pneumonia infection was significantly more prevalent in MS patients than in healthy individuals (p< .05). MS patients were more likely to suffer from common colds (p< .05), but no significant difference was observed regarding other infectious diseases (p> .05). Additionally, the prevalence of chronic infections was higher among MS patients (p< .05).
Conclusion: M.pneumoniae infection, common colds, and chronic infections were significantly more common in MS patients than in healthy controls. However, no significant association was found between other infectious diseases and MS risk. These findings emphasize the possible role of specific pathogens in MS development, warranting further investigation into underlying mechanisms and contributing factors.
Full-Text [PDF 411 kb]   (117 Downloads)    
Article Type: Original Research | Subject: Bacteriology
Received: 2024/10/5 | Accepted: 2024/11/20 | Published: 2025/02/22

References
1. Ahmad R, Ahsan H. Dual autoimmune diseases: Rheumatoid arthritis with systemic lupus erythematosus and Type 1 diabetes mellitus with multiple sclerosis. Rheumatol Autoimmun. 2022;2(3):120-8.
2. Hosseinzadeh A, Baneshi MR, Sedighi B, Kermanchi J, Haghdoost AA. Incidence of multiple sclerosis in Iran: A nationwide, population-based study. Public Health. 2019;175:138-44.
3. Yamout BI, Assaad W, Tamim H, Mrabet S, Goueider R. Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region. Mult Scler J Exp Transl Clin. 2020;6(1):2055217319841881.
4. Eskandarieh S, Molazadeh N, Moghadasi AN, Azimi AR, Sahraian MA. The prevalence, incidence, and familial recurrence of multiple sclerosis in Tehran, Iran. Mult Scler Relat Disord. 2018;25:143.
5. Legroux L, Arbour N. Multiple sclerosis and T lymphocytes: An entangled story. J Neuroimmune Pharmacol. 2015;10(4):528-46.
6. Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: Entering an era. Ann Neurol. 2018;83(1):13-26.
7. Marabita F, Almgren M, Sjöholm LK, Kular L, Liu Y, James T, et al. Smoking induces DNA methylation changes in multiple sclerosis patients with exposure-response relationship. Sci Rep. 2017;7(1):14589.
8. Pourostadi M, Sattarpour S, Poor BM, Asgharzadeh M, Kafil HS, Farhoudi M, et al. Vitamin D receptor gene polymorphism and the risk of multiple sclerosis in the Azeri population of Iran. Endocr Metab Immune Disord Drug Targets. 2021;21(7):1306-11.
9. Asgharzadeh M, Sanajoo D, Mahdavi Poor B, Samadi Kafil H, Gholizadeh P, Rashedi J. Interleukin-10 promoter and the CCR5 polymorphisms in Iranian Azari population with multiple sclerosis. Iran J Immunol. 2021;18(3):241-8.
10. Asgharzadeh V, Rezaei SA, Poor BM, Asgharzadeh M, Nobari HJ, Taghinejad Z, et al. The association between diet and multiple sclerosis. Endocr Metab Immune Disord Drug Targets. 2024;24(8):909-17.
11. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle, and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25-36.
12. Mihailova S, Ivanova M, Mihaylova A, Quin L, Mikova O, Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol. 2005;168(1-2):138-43.
13. Laxminarayana D. Molecular insights into onset of autoimmunity in SARS-CoV-2 infected patients. Rheumatol Autoimmun. 2022;2(4):198-202.
14. Bahar M, Ashtari F, Aghaei M, Akbari M, Salari M, Ghalamkari S. Mycoplasma pneumonia seropositivity in Iranian patients with relapsing-remitting multiple sclerosis: A randomized case-control study. J Pak Med Assoc. 2012;62(3 Suppl 2):S6-8.
15. Kaskow BJ, Baecher-Allan C. Effector T cells in multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(4):a029025.
16. Libbey JE, Cusick MF, Fujinami RS. Role of pathogens in multiple sclerosis. Int Rev Immunol. 2014;33(4):266-83.
17. Ha EK, Kim JH, Cha HR, Han BE, Shin YH, Baek HS, et al. Investigating the occurrence of autoimmune diseases among children and adolescents hospitalized for Mycoplasma pneumoniae infections. Front Immunol. 2023;14:1165586.
18. Maida E. Immunological reactions against Mycoplasma pneumoniae in multiple sclerosis: Preliminary findings. J Neurol. 1983;229(2):103-11.
19. Abrahamyan S, Eberspächer B, Hoshi MM, Aly L, Luessi F, Groppa S, et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(7):681-6.
20. He R, Du Y, Wang C. Epstein-Barr virus infection: The leading cause of multiple sclerosis. Signal Transduct Target Ther. 2022;7(1):239.
21. Kawada JI, Ito Y, Ohshima K, Yamada M, Kataoka S, Muramatsu H, et al. Updated guidelines for chronic active Epstein-Barr virus disease. Int J Hematol. 2023;118(5):568-76.
22. Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):51-64.
23. Khalili N, Khalili N, Nickhah A, Khalili B. Seroprevalence of anti-Toxocara antibody among multiple sclerosis patients: A case-control study. J Parasit Dis. 2020;44(1):145-50.
24. Nicoletti A, Cicero CE, Giuliano L, Todaro V, Lo Fermo S, Chisari C, et al. Toxoplasma gondii and multiple sclerosis: A population-based case-control study. Sci Rep. 2020;10(1):18855.
25. Correale J, Farez MF. The impact of environmental infections (parasites) on MS activity. Mult Scler. 2011;17(10):1162-9.
26. Sayama A, Okamoto M, Tamaki R, Saito-Obata M, Saito M, Kamigaki T, et al. Comparison of rhinovirus A-, B-, and C-associated respiratory tract illness severity based on the 5'-untranslated region among children younger than 5 years. Open Forum Infect Dis. 2022;9(10):ofac387.
27. Kriesel JD, Sibley WA. The case for rhinoviruses in the pathogenesis of multiple sclerosis. Mult Scler. 2005;11(1):1-4.
28. Nicolson GL, Haier J. Role of chronic bacterial and viral infections in neurodegenerative, neurobehavioral, psychiatric, autoimmune, and fatiguing illnesses: Part 1. Br J Med Pract. 2009;2(4):20-8
29. Cossu D, Yokoyama K, Hattori N. Bacteria-host interactions in multiple sclerosis. Front Microbiol. 2018;9:2966.
30. Fainardi E, Castellazzi M, Seraceni S, Granieri E, Contini C. Under the microscope: Focus on Chlamydia pneumoniae infection and multiple sclerosis. Curr Neurovasc Res. 2008;5(1):60-70.
31. Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ. Vision in multiple sclerosis: The story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol. 2011;31(4):362-73.
32. Sewell DL, Reinke EK, Co DO, Hogan LH, Fritz RB, Sandor M, et al. Infection with Mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigen-specific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin Diagn Lab Immunol. 2003;10(4):564-72.
33. Jaruvongvanich V, Sanguankeo A, Jaruvongvanich S, Upala S. Association between Helicobacter pylori infection and multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2016;7:92-7.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.